FDA allows marketing of first A1c test labeled for diagnosing diabetes
Today the U.S. Food and Drug Administration announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay) for the diagnosis of diabetes by health care professionals. This is the first HbA1c test …
See all stories on this topic »
Shape Magazine Sparks Explosive Interest in Limitless Worldwide(TM), LLC
SALT LAKE CITY, May 22, 2013 /PRNewswire/ — Limitless Worldwide(TM), LLC, only made its official debut three months ago, yet it's already becoming one of the most talked about network marketing companies in the world. The latest to add fuel to the …
See all stories on this topic »
Social media marketing replaces traditional ads for small businesses
In order to achieve a bigger social media presence, businesses are willing to reduce spend on other traditional marketing methods. For instance, some 26% plan to cut back on local directory inclusions and 24% will reduce local advertising activity …
See all stories on this topic »
Popular Questions
What does the FDA allowing marketing of the first A1c test labeled for diagnosing diabetes mean?
The FDA decision allows the test to be marketed with a specific indication for helping diagnose diabetes. A1c testing measures average blood glucose levels over roughly the previous two to three months. Patients should discuss results with a qualified healthcare professional, who can interpret them alongside symptoms and other clinical information.
How can the first FDA-authorized A1c test labeled for diagnosing diabetes be used?
The test may be used by healthcare professionals as part of an evaluation for diabetes. Because an A1c result can be affected by certain medical conditions and individual circumstances, it should not be interpreted in isolation. Follow-up testing or additional assessment may be appropriate when a result is abnormal or does not match a patient’s clinical picture.
Why is FDA clearance of an A1c test labeled for diagnosing diabetes important?
The authorization distinguishes this test from A1c products marketed only for monitoring glucose in people already diagnosed with diabetes. It gives healthcare providers another regulated option for assessing longer-term blood glucose levels during diagnostic evaluation. The FDA decision does not mean every person should self-diagnose based on a single test result.
Does the first A1c test labeled for diagnosing diabetes replace other diabetes tests?
No, the FDA-authorized A1c test does not automatically replace fasting glucose, oral glucose tolerance, or other diagnostic assessments. Clinicians choose tests based on the patient’s health history, symptoms, and the reliability of the available results. Anyone receiving a concerning A1c result should seek professional follow-up rather than changing treatment without medical advice.